PubMed · 7187159
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
R Schröder. 1982. [Systemic or selective lysis?].. https://pubmed.ncbi.nlm.nih.gov/7187159/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Explore the source record for details and available documents.
The hibernating myocardium refers to the presence of persistent myocardial and left ventricular dysfunction at rest, due to reduced coronary blood flow. This left ventricular dysfunction represents an endogenous adaptive mechanism which prevents irreversible cell damage. The dysfunction in hibernating myocardium improves following restoration of coronary blood flow. A key concept in hibernating myocardium is that the reduction in contractile function induced by ischaemia has a protective effect. By reducing oxygen demand the myocardium maintains its viability in the setting of limited oxygen supply. The hibernating myocardium is a new metabolic state that is a consequence of an ischaemic condition, but the hibernating cardiomyocytes are not necessarily ischaemic. There are no adequate animal models for chronic hibernation. However, there are models for acute hibernation both in intact beating hearts and in isolated hearts. In these models a stable reduction in mechanical function for some hours has been demonstrated, whereas metabolic indicators of ischaemia improve during sustained low-flow ischaemia.
Nisoldipine is a second-generation dihydropyridine calcium antagonist structurally related to nifedipine and used in the treatment of stable angina and arterial hypertension. It is also under investigation for the treatment of left ventricular dysfunction. It was first developed as an immediate release tablet, but this formulation was not considered optimal for once-daily administration because of the variable results obtained at peak and trough in clinical studies. Consequently, nisoldipine coat core (CC) was developed with the aim of optimizing the drug's time--effect profile over the 24-hour dosing interval. The in vitro release pattern classifies this tablet as an "extended release" formulation according to European Community guidelines. The present article outlines the pharmacokinetic and pharmacodynamic profiles of nisoldipine CC, as obtained from recent clinical studies.